TNFSF13B and systemic lupus erythematosus: Randomized placebo-controlled trials in SLE patients, ILLUMINATE-1 and ILLUMINATE-2, both demonstrate biological activity, changes in anti-dsDNA, complement, B-cells, and immunoglobulins consistent with BAFF pathway inhibition.